Cancer drug prices may fall as margins to be capped at 30%

Cancer patients in the country may soon experience a significant reduction in the cost of some of the most expensive medicines on the market. The government plans to cap trade margins at 30% on these drugs, which could lead to an average price decrease of up to 70% for the affected medications, according to sources within the Department of Pharmaceuticals. This initiative aims to address the issue of exorbitant mark-ups in the cancer drug market, which has been exacerbated by the pandemic.

The government's decision follows a similar pilot program implemented in 2019, which capped trade margins on 42 cancer medicines. The new regulation is specifically targeted at high-priced drugs, where even a modest margin can result in a substantial increase in the patient's overall expenses. A committee led by the Director General of Health Services is currently compiling a list of medicines that will be subject to the new trade margin cap.

To qualify for the regulation, the drugs must be approved for cancer treatment in India, be frequently used, and be expensive. A Department of Pharmaceuticals official emphasized that a primary factor in selecting these medicines is their expense, as the regulated margin must be sufficient to cover marketing and distribution costs.

The government aims to avoid a blanket cap on all drugs, including cheaper ones, as this could discourage companies from marketing such products due to the regulated margin not adequately compensating for those additional expenses.

By focusing on the most costly cancer therapies, the new regulation could have a significant impact on the pricing of these treatments in India. If successfully implemented, this measure could potentially bring down the maximum retail prices of some of the most expensive cancer drugs available in the country, ultimately benefiting cancer patients by reducing their financial burden.